...Franz Stanzel Background: Several studies have indicated that intrapleural infusion of bevacizumab is an effective treatment for non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE). However, the impact of bevacizumab administered through an indwelling pleural catheter (IPC...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Non-small cell lung cancer Immune checkpoint inhibitor Nanoparticle albumin-bound paclitaxel Subsequent...

...Thomas Lesser Background: N2 stage disease constitutes approximately 20%–30% of all non-small cell lung cancer (NSCLC). Concurrently, surgery remains the first-choice treatment for patients with N2 NSCLC if feasible. However, the role of pneumonectomy in N2 NSCLC has rarely been investigated...

..., Klinik für Innere Medizin II, Halle (Saale), Deutschland Abstract aus Gutiérrez L, Royuela A, Carcereny E, et al.: Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. BMC Cancer. 2021;21(1):977. Keywords Non-small cell...

...Khosro Hekmat Approximately 30% of patients with non-small-cell lung cancer (NSCLC) present with localized/non-metastatic disease and are eligible for surgical resection or other «treatment with curative intent». Due to the high prevalence of recurrence after treatment, adjuvant therapy is standard...

..., instructions or products referred to in the content or advertisements. Non-small cell lung cancer Immune-related adverse events Immunotherapy Prognostic factor Die Patienten, welche immunvermittelte Nebenwirkungen aufwiesen, wurden retrospektiv zudem in eine Gruppe mit therapeutischem...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Non-small cell lung cancer Nivolumab Pembrolizumab Atezolizumab EGFR KRAS...

... with advanced non-small cell lung cancer (NSCLC) in Asian subsets. The number of brain metastases (BM) is relatively higher in EGFR mutation-positive patients compared to EGFR wild-type patients. The objective of this study is to evaluate the efficacy of RAM + DOC focusing on EGFR mutation and BM. Methods: We...

...Susanne Horter; Wolfgang Schütte Aims: Non-small cell lung cancer (NSCLC) patients with EGFR mutations do not respond well to checkpoint inhibitors. However, little is known about the activity of immunotherapy in NSCLC with other driver mutations. The increasing use of next-generation sequencing...

... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2020 Non-small cell lung cancer Stage II...

...Niels Reinmuth Background: The role of microRNA-133a (miR-133a) in non-small cell lung cancers (NSCLCs) is controversial. Thus, we conducted a comprehensive study based on meta-analysis and The Cancer Genome Atlas (TCGA) database. Methods: Publications were searched in both English and Chinese...

... cancer Mutation Genomics SNPs Small cell lung cancer Non-small cell lung cancer Jahrzehntelang war die Arbeit des Pathologen mit der Einteilung des Lungenkarzinoms in «Kleinzeller» oder «Nichtkleinzeller (Adenokarzinom oder Plattenepithelkarzinom)» getan, da differenzierte Therapien...